Global Crysvita Injection Market Growth 2025-2031
Description
The global Crysvita Injection market size is predicted to grow from US$ 72.6 million in 2025 to US$ 88.9 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
X-linked hypophosphatemia, or XLH, is a hereditary skeletal disease triggered by excess production of the hormone fibroblast growth factor 23. FGF23 causes phosphate urinary excretion and hinders patients" ability to produce vitamin D. CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Brosumab (burosumab, trade name Crysvita) is a recombinant fully humanized monoclonal IgG1 antibody targeting fibroblast growth factor 23 (FGF23) jointly developed by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin. In February 2018, the drug was conditionally approved by the European Union for the treatment of X-linked hypophosphatemia (XLH) in children and adults aged 1 and above, becoming the world"s first XLH treatment drug, and it was approved by the FDA in April of the same year indications. In September of the following year, the drug was approved by the FDA to expand the indication population to infants as young as 6 months old. FGF23 is a bone-derived hormone that regulates the metabolism of phosphorus and vitamin D. It can block the reabsorption of phosphate by the kidney and inhibit the absorption of vitamin D-dependent phosphate, resulting in a significant decrease in the level of phosphate in the blood. It is XLH main culprit. XLH is a rare genetic disorder and the most common form of hypophosphatemic rickets, affecting 1 in 20,000 people. XLH is carried on the X chromosome, and while nearly all X-linked disorders are recessive, XLH is one of the few that is inherited in a dominant manner.
LP Information, Inc. (LPI) ' newest research report, the “Crysvita Injection Industry Forecast” looks at past sales and reviews total world Crysvita Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Crysvita Injection sales for 2025 through 2031. With Crysvita Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Crysvita Injection industry.
This Insight Report provides a comprehensive analysis of the global Crysvita Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Crysvita Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Crysvita Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Crysvita Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Crysvita Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Crysvita Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
10 mg/mL
20 mg/mL
30 mg/mL
Segmentation by Application:
Children
Adults
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Kyowa Kirin
Ultragenyx Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Crysvita Injection market?
What factors are driving Crysvita Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Crysvita Injection market opportunities vary by end market size?
How does Crysvita Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
X-linked hypophosphatemia, or XLH, is a hereditary skeletal disease triggered by excess production of the hormone fibroblast growth factor 23. FGF23 causes phosphate urinary excretion and hinders patients" ability to produce vitamin D. CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Brosumab (burosumab, trade name Crysvita) is a recombinant fully humanized monoclonal IgG1 antibody targeting fibroblast growth factor 23 (FGF23) jointly developed by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin. In February 2018, the drug was conditionally approved by the European Union for the treatment of X-linked hypophosphatemia (XLH) in children and adults aged 1 and above, becoming the world"s first XLH treatment drug, and it was approved by the FDA in April of the same year indications. In September of the following year, the drug was approved by the FDA to expand the indication population to infants as young as 6 months old. FGF23 is a bone-derived hormone that regulates the metabolism of phosphorus and vitamin D. It can block the reabsorption of phosphate by the kidney and inhibit the absorption of vitamin D-dependent phosphate, resulting in a significant decrease in the level of phosphate in the blood. It is XLH main culprit. XLH is a rare genetic disorder and the most common form of hypophosphatemic rickets, affecting 1 in 20,000 people. XLH is carried on the X chromosome, and while nearly all X-linked disorders are recessive, XLH is one of the few that is inherited in a dominant manner.
LP Information, Inc. (LPI) ' newest research report, the “Crysvita Injection Industry Forecast” looks at past sales and reviews total world Crysvita Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Crysvita Injection sales for 2025 through 2031. With Crysvita Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Crysvita Injection industry.
This Insight Report provides a comprehensive analysis of the global Crysvita Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Crysvita Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Crysvita Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Crysvita Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Crysvita Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Crysvita Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
10 mg/mL
20 mg/mL
30 mg/mL
Segmentation by Application:
Children
Adults
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Kyowa Kirin
Ultragenyx Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Crysvita Injection market?
What factors are driving Crysvita Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Crysvita Injection market opportunities vary by end market size?
How does Crysvita Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
76 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Crysvita Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Crysvita Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
